Justin B. Klee - Jan 6, 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Justin Klee
Stock symbol
AMLX
Transactions as of
Jan 6, 2022
Transactions value $
$0
Form type
3
Date filed
1/6/2022, 04:06 PM
Next filing
May 6, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AMLX Common Stock 2.48M Jan 6, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AMLX Stock Option (Right to Buy) Jan 6, 2022 Common Stock 335K $0.37 Direct F1
holding AMLX Stock Option (Right to Buy) Jan 6, 2022 Common Stock 100K $1.57 Direct F2
holding AMLX Stock Option (Right to Buy) Jan 6, 2022 Common Stock 200K $7.57 Direct F3
holding AMLX Series C-1 Preferred Stock Jan 6, 2022 Common Stock 4.87K Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 6,977 shares subject to such stock option vested and became exercisable on March 16, 2018 and the remainder of the shares vest in monthly installments of 6,969 shares for a period of 47 months after the vesting commencement date.
F2 25,012 shares subject to such option vested and became exercisable on February 26, 2021 and the remainder of the shares vest in monthly installments of 2,083 shares thereafter.
F3 50,024 shares subject to such option shall vest and become exercisable on February 19, 2022 and the remainder of the shares vest in monthly installments of 4,166 shares thereafter.
F4 Each share of Series C-1 preferred stock is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Series C-1 Preferred stock has no expiration date.